News & Updates
Filter by Specialty:
Objective response to systemic therapy linked to overall survival in unresectable HCC
23 Jan 2023
byStephen Padilla
Objective response to first-line systemic therapy with lenvatinib or sorafenib independently predicts overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC), as shown by the subanalysis of the REFLECT study.